Cargando…
Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus—Cumulative Observational Data from Four Recent Clinical Studies
Objectives: To investigate pivmecillinam´s efficacy in uncomplicated lower urinary tract infection (UTI) caused by Staphylococcus saprophyticus—considered non-susceptible to mecillinam. Methods: Participants with confirmed UTIs caused by S. saprophyticus from four randomized controlled trials, where...
Autores principales: | Jansåker, Filip, Bollestad, Marianne, Vik, Ingvild, Lindbæk, Morten, Bjerrum, Lars, Frimodt-Møller, Niels, Knudsen, Jenny Dahl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628187/ https://www.ncbi.nlm.nih.gov/pubmed/31067667 http://dx.doi.org/10.3390/antibiotics8020057 |
Ejemplares similares
-
The efficacy of pivmecillinam: 3 days or 5 days t.i.d against community acquired uncomplicated lower urinary tract infections – a randomized, double-blinded, placebo-controlled clinical trial study protocol
por: Jansåker, Filip, et al.
Publicado: (2016) -
Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women—A double-blind, randomized non-inferiority trial
por: Vik, Ingvild, et al.
Publicado: (2018) -
Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial()
por: Jansåker, Filip, et al.
Publicado: (2019) -
The Risk of Pyelonephritis Following Uncomplicated Cystitis: A Nationwide Primary Healthcare Study
por: Jansåker, Filip, et al.
Publicado: (2022) -
Predictors of Symptom Duration and Bacteriuria in Uncomplicated Urinary Tract Infection
por: Bollestad, Marianne, et al.
Publicado: (2018)